PDF herunterladen
Aktuelle Dermatologie 2012; 38(10): 386-392
DOI: 10.1055/s-0032-1310029
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Melanom und M. Parkinson

Gibt es eine erhöhte Inzidenz für das gemeinsame Auftreten beider Erkrankungen?Melanoma and Parkinson’s DiseaseIs there an Increased Incidence of the Common Occurrence of Both Diseases?
C. Börsch
1   Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf
,
I. Moll
1   Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf
,
M. O. Koch
2   Neurologie Toggenburg, Wattwil/Schweiz
,
U. Hauswirth
3   Dermatologie Toggenburg, Wattwil/Schweiz
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
17. Juli 2012 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Seit längerem wird ein kausaler Zusammenhang respektive eine Koinzidenz zwischen Melanom und M. Parkinson diskutiert, insbesondere nach Einführung von L-Dopa-Präparaten in der Parkinson-Therapie. Die Literatur ergibt jedoch ein widersprüchliches Bild. In der vorliegenden Studie mit 1174 Melanompatienten konnte kein gehäuftes Auftreten von malignem Melanom und M. Parkinson demonstriert werden. Nur 0,94 % der Melanompatienten wiesen einen M. Parkinson auf. Das Risiko eines Melanompatienten, an einem M. Parkinson zu erkranken, lag bei 0,77 %. Außerdem ergab sich kein Hinweis für einen kausalen Zusammenhang zwischen der Einnahme eines L-Dopa-Präparates und dem Auftreten eines Melanoms. Bei den Melanompatienten zeigte sich in Einklang mit der Literatur eine Übereinstimmung im durchschnittlichen Erstdiagnosealter, in der ausgewogenen Geschlechterverteilung, bei den Melanomsubtypen, bei den Tumordicken und der Lokalisation. Im Parkinsonkollektiv ergaben sich Tendenzen zu einem späteren Auftreten sowie zu dünneren Melanomen. Ansonsten zeigten sich bei den Parkinsonpatienten in Bezug auf Geschlechterverteilung und Lokalisation keine gravierenden Unterschiede gegenüber den ausschließlichen Melanompatienten.

Abstract

For a long time a causal relationship respectively a coincidence between melanoma and Parkinson’s disease has been discussed, especially after the introduction of L-dopa preparations in Parkinson’s therapy. However, the literature showes a conflicting picture. In the present study with 1,174 melanoma patients there is no increased incidence of malignant melanoma and Parkinson’s disease demonstrated. Only 0.94 % of melanoma patients had a Parkinson’s disease. The risk of a patient with Parkinson’s disease was 0.77 %. In addition, we found no evidence for a causal association between the use of an L-dopa preparation and the occurrence of melanoma. In the group of melanoma patients there has been demonstrated similar results as in literature, concerning age of manifestation, gender balance, distribution in melanoma subtypes, tumor thickness and location. The Parkinson’s collective has been shown tendencies to a later onset and to thinner melanomas. With regard to gender distribution and localization no significant differences compared to the exclusive melanoma patients have been demonstrated in the Parkinson’s disease group.

 

  • Literatur

  • 1 Balch CM, Soong SJ, Shaw HM, Milton GW. An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In: Balch CM, Milton GW, Hrsg. Cutaneous melanoma. Clinical management and treatment results worldwide. Philadelphia: Lippincott; 1985: 321-352
    Suche in Google Scholar
  • 2 Balch CM, Soong SJ, Shaw HM et al. An analysis of prognostic factors in 8500 patients with cutaneous malignant melanoma. In: Balch CM, ed. Cutaneous melanoma. Philadelphia: Lippincott; 1992: 165-187
    Suche in Google Scholar
  • 3 Balch CM, Buzald AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19 (Suppl. 16) 3635-3648
    PubMedSuche in Google Scholar
  • 4 Barnhill RL MJM, Fitzpatrick TB, Sober AJ. Neoplasms: Malignant melanoma. Dermatology in General Medicine. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., Hrsg. Dermatology in General Medicine. New York: Mc Graw-Hill; 1993: 1078-1115
    Suche in Google Scholar
  • 5 Beardmore GL. The epidemiology of malignant melanoma in Australia. In: McCarthy WH, ed. Melanoma and Skin cancer Blight. Sidney: VCN; 1972: 39-64
    Suche in Google Scholar
  • 6 Bertonie JM, Arlette JP, Fernandez HH et al. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 2010; 67 (Suppl. 03) 347-52
    CrossrefPubMedSuche in Google Scholar
  • 7 Blum A, Garbe C. Epidemiologie, Prävention und Nachsorge maligner Melanome. Onkologe 2001; 7: 18-35
    CrossrefPubMedSuche in Google Scholar
  • 8 Buhmann C. Therapy of geriatric patients with Parkinson’s disease. Akt Neurol 2009; 36: 312-319
    Thieme ConnectPubMedSuche in Google Scholar
  • 9 Dodel RC, Singer M, Kohne-Volland R et al. The economic impact of Parkinson’s disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998; 14: 299-312
    CrossrefPubMedSuche in Google Scholar
  • 10 Ferreira JJ, Neutel D, Mestre T et al. Skin cancer and Parkinson’s disease. Movement Disorders 2010; 25: 139-148
    CrossrefPubMedSuche in Google Scholar
  • 11 Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence?. Parkinsonism Relat Disord 2003; 9: 321-327
    CrossrefPubMedSuche in Google Scholar
  • 12 Garbe C, Büttner P, Bertz J et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995; 75: 2484-2491
    CrossrefPubMedSuche in Google Scholar
  • 13 Garbe C, Büttner P, Ellwanger U et al. Das Zentralregister Malignes Melanom der Deutschen Dermatologischen Gesellschaft in den Jahren 1983 – 1993. Hautarzt 1995; 46: 683-692
    CrossrefPubMedSuche in Google Scholar
  • 14 Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14: 280-290
    CrossrefPubMedSuche in Google Scholar
  • 15 Garbe C. Therapiekonzepte Onkologie – Malignes Melanom. In: Seeber S, Schüller J, Hrsg. Berlin: Springer; 2003: 1057-1087
    Suche in Google Scholar
  • 16 Giles GG, Armstrong BK, Burton RC et al. Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994.. BMJ 1996; 312: 1121-1125
    CrossrefPubMedSuche in Google Scholar
  • 17 Inzelberg R, Rabey JM, Melamed E et al. High prevalence of malignant melanoma in Israeli patient with Parkinson’s disease. J Neural Transm 2011; 118 (Suppl. 08) 1199-1207
    CrossrefPubMedSuche in Google Scholar
  • 18 Katalinic A, Kunze U, Schafer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 2003; 149: 1200-1206
    CrossrefPubMedSuche in Google Scholar
  • 19 Katzenschlager R, Head J, Schrag A et al. Parkinson’s Disease Research Group of the United Kingdom (2008) Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. In: Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 2009; 373: 2055-2066
    CrossrefPubMedSuche in Google Scholar
  • 20 Kincannon J, Boutzale C. The physiology of pigmented nevi. Pediatrics 1999; 104: 1042-1045
    PubMedSuche in Google Scholar
  • 21 Liu R, Gao X, Lu Y et al. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011; 76 (Suppl. 23) 2002-2009
    CrossrefPubMedSuche in Google Scholar
  • 22 Lo RY, Tanner CM, Van Den Eeden SK et al. Comorbid cancer in Parkinson’s disease. Mov Disord 2010; 25 (Suppl. 12) 1809-1817
    CrossrefPubMedSuche in Google Scholar
  • 23 MacKie RM. Malignes Melanom, Klinische Varianten und prognostische Indikatoren. Z f Hautkr 2000; 9: 518-522
    PubMedSuche in Google Scholar
  • 24 MacKie RM, Bray CA, Hole DJ et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002; 360: 587-591
    CrossrefPubMedSuche in Google Scholar
  • 25 Mansson-Brahme E, Johansson H, Larsson O et al. Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976-1994. Acta Oncol 2002; 41: 138-146
    CrossrefPubMedSuche in Google Scholar
  • 26 Meng S, Song F, Chen H et al. No association between Parkinson disease alleles and the risk of melanoma. Cancer Epidemiol Biomarkers Prev 2012; 21 (Suppl. 01) 243-245
    CrossrefPubMedSuche in Google Scholar
  • 27 Marks R. The changing incidence and mortality of melanoma in Australia. Recent Results Cancer Res 2002; 60: 113-121
    PubMedSuche in Google Scholar
  • 28 Olsen JH, Friis S, Frederiksen K et al. Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 2005; 92: 201-205
    CrossrefPubMedSuche in Google Scholar
  • 29 Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 2006; 17: 582-587
    CrossrefPubMedSuche in Google Scholar
  • 30 Olsen JH, Jorgensen TL, Rugbjerg K et al. Parkinson disease and malignant melanoma in first-degree relatives of patients with early-onset melanoma. Epidemiology 2011; 22 (Suppl. 01) 109-112
    CrossrefPubMedSuche in Google Scholar
  • 31 Paisan-Riuz C, Houlden H. Common pathogenetic pathways in melanoma an Parkinson disease. Neurology 2010; 75 (Suppl. 18) 1653-1655
    CrossrefPubMedSuche in Google Scholar
  • 32 Pan T, Li X, Jankovic J. The association between Parkinson’s disease and melanoma. Int J Cancer 2011; 128 (Suppl. 10) 2251-2260
    CrossrefPubMedSuche in Google Scholar
  • 33 Perniciaro C. Dermatopathologic variants of malignant melanoma. Mayo Clin Proc 1997; 72: 273-279
    CrossrefPubMedSuche in Google Scholar
  • 34 Pfützner W, Przybilla B. Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature.. J Am Acad Dermatol 1997; 37: 332-336
    CrossrefPubMedSuche in Google Scholar
  • 35 Rauh M, Paul E, Illig L. Incidence of malignant melanoma in Central Hesse, Germany. Anticancer Res 1987; 7: 447-448
    PubMedSuche in Google Scholar
  • 36 Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson’s disease on health status, health expenditures, and productivity. Estimates from the National Medical Expenditure Survey. Pharmacoeconomics 1997; 12: 486-498
    CrossrefPubMedSuche in Google Scholar
  • 37 Sandyk R. Accelerated growth of malignant melanoma by levodopa in Parkinson’s disease and the role of the pineal gland. Int J Neurosci 1992; 63: 137-140
    CrossrefPubMedSuche in Google Scholar
  • 38 Siple JF, Schneider DC, Wanlass WA et al. Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 2000; 34: 382-385
    CrossrefPubMedSuche in Google Scholar
  • 39 Skibba JL, Pinckley J, Gilbert EF et al. Multiple primary melanoma following administration of levodopa. Arch Pathol 1972; 93: 556-561
    PubMedSuche in Google Scholar
  • 40 Stang A, Jockel KH. Changing patterns of skin melanoma mortality in West Germany from 1968 through 1999. Ann Epidemiol 2003; 13: 436-442
    CrossrefPubMedSuche in Google Scholar
  • 41 Van Den Eeden SK, Tanner CM, Bernstein AL et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015-1022
    CrossrefPubMedSuche in Google Scholar
  • 42 von Seebach HB, Tille MM, Bahmer F. Malignant melanoma of the skin in the Saarland cancer registry 1968 – 1981. Pathologe 1985; 6: 231-241
    PubMedSuche in Google Scholar